DeepMed Research

Ticagrelor

Generic Name: Ticagrelor

Brand Names: Brilinta, Brilique

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈F_₂N_₆O_₄S

CAS Number: 274693-27-5

Unique Ingredient Identifier: GLH0314RVC

Background: Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication: Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions: Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)

Clinical Trials

Ticagrelor Versus Cilostazol in Ischemic Stroke

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Cilostazol 100 MG
Drug: Ticagrelor 90 MG

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-20

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06561867

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rosuvastatin
Drug: Ticagrelor

First Posted Date: 2024-08-15

Last Posted Date: 2025-04-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 28

Registration Number: NCT06554821

Locations: 🇩🇪
Research Site, Berlin, Germany

Ticagrelore Alone Post PCI

Phase 4

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Ticagrelor 90 MG
Drug: aspirin 80 mg and clopidogrel 75 mg daily

First Posted Date: 2024-07-19

Last Posted Date: 2025-05-21

Lead Sponsor: Shiraz University of Medical Sciences

Target Recruit Count: 5400

Registration Number: NCT06509893

Locations: 🇮🇷
Cardiology Ward Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
🇮🇷
professor Kojuroi cardiology clinic, Shiraz, Iran, Islamic Republic of

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Phase 4

Not yet recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Aspirin
Drug: Indobufen
Drug: Ticagrelor

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-18

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 2846

Registration Number: NCT06451198

Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

Phase 4

Recruiting

Conditions: Intracranial Aneurysm

Interventions: Drug: ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
Drug: combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).

First Posted Date: 2024-05-06

Last Posted Date: 2024-05-06

Lead Sponsor: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Target Recruit Count: 640

Registration Number: NCT06400940

Locations: 🇷🇺
V.A. Almazov Fnmrc, Saint-petersburg, Russian Federation

TADCLOT- a Double Blind Randomized Controlled Trial

Phase 3

Recruiting

Conditions: Myocardial Infarction, Acute
Stent Thrombosis

Interventions: Drug: Ticagrelor 90 MG
Drug: Clopidogrel

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-19

Lead Sponsor: National Institute of Cardiovascular Diseases, Pakistan

Target Recruit Count: 2200

Registration Number: NCT06318481

Locations: 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, SIndh, Pakistan

A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge

Not Applicable

Recruiting

Conditions: Vertebral Artery Stenosis
Brain Disease

Interventions: Drug: Ticagrelor

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: The Fourth Affiliated Hospital of China Medical University

Target Recruit Count: 560

Registration Number: NCT06301776

Locations: 🇨🇳
the Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Phase 4

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Ticagrelor 60mg
Drug: Clopidogrel

First Posted Date: 2024-01-29

Last Posted Date: 2025-04-24

Lead Sponsor: University of Florida

Target Recruit Count: 50

Registration Number: NCT06228456

Locations: 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Cilostazol 100 MG

First Posted Date: 2024-01-11

Last Posted Date: 2024-08-20

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 580

Registration Number: NCT06202755

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Cilostazol 100 MG

First Posted Date: 2024-01-09

Last Posted Date: 2024-08-20

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06196047

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy